Literature DB >> 2167382

A molecular and serologic evaluation of enteroviral involvement in human myocarditis.

S Tracy1, N M Chapman, B M McManus, M A Pallansch, M A Beck, J Carstens.   

Abstract

Murine coxsackie B virus infection models of myocarditis and numerous human serologic studies associating elevated enterovirus-specific IgM titers with the clinical diagnosis of myocarditis have been used to support an etiologic role for enteroviruses in human myocarditis. Of the human enteroviruses, coxsackie B viruses (CVB) are the enterovirus group most commonly associated with the human disease. While hybridization probes exist to detect most, if not all, human enteroviruses, no probe capable of specifically detecting an enteroviral group (such as the CVB) to the exclusion of all others has been described to date. Thus, to test the hypothesis that enteroviral involvement in human myocarditis is commonplace, we examined a case series of human myocarditic heart tissues for enteroviruses by in situ hybridization using a generic enterovirus probe. These results were then compared with CVB-specific IgM levels in the cognate patient sera. Comparison of the hybridization data with the CVB-specific IgM levels in the cognate sera yielded no valid correlation between the detection of enteroviral RNA and specificity of CVB identification in any patient. The data are consistent with common enterovirus infections in humans and a possible etiologic role in myocarditis but do not support a specific etiologic role for CVB in this study group.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2167382     DOI: 10.1016/0022-2828(90)91476-n

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  28 in total

1.  Detection of enteroviruses in cell cultures by using in situ transcription.

Authors:  J M Carstens; S Tracy; N M Chapman; C J Gauntt
Journal:  J Clin Microbiol       Date:  1992-01       Impact factor: 5.948

2.  [Pathogenesis of inflammatory cardiomyopathies].

Authors:  H P Schultheiss; M Pauschinger; U Kühl
Journal:  Med Klin (Munich)       Date:  1998-04-15

3.  Toward testing the hypothesis that group B coxsackieviruses (CVB) trigger insulin-dependent diabetes: inoculating nonobese diabetic mice with CVB markedly lowers diabetes incidence.

Authors:  S Tracy; K M Drescher; N M Chapman; K-S Kim; S D Carson; S Pirruccello; P H Lane; J R Romero; J S Leser
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

4.  Expression of an antigenic adenovirus epitope in a group B coxsackievirus.

Authors:  K Höfling; S Tracy; N Chapman; K S Kim; J Smith Leser
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

5.  Intracellular viral localization in murine coxsackievirus-B3 myocarditis. Ultrastructural study by electron microscopic in situ hybridization.

Authors:  A Ukimura; H Deguchi; Y Kitaura; S Fujioka; M Hirasawa; K Kawamura; K Hirai
Journal:  Am J Pathol       Date:  1997-06       Impact factor: 4.307

Review 6.  [Enteroviral myocarditis and dilated cardiomyopathy].

Authors:  R Kandolf
Journal:  Med Klin (Munich)       Date:  1998-04-15

Review 7.  [Cardiotropic DNA viruses and bacteria in the pathogenesis of dilated cardiomyopathy with or without inflammation].

Authors:  S Pankuweit; G Hufnagel; H Eckhardt; H Herrmann; S Uttecht; B Maisch
Journal:  Med Klin (Munich)       Date:  1998-04-15

Review 8.  Viral myocarditis: from experimental models to molecular diagnosis in patients.

Authors:  Sabine Pankuweit; Karin Klingel
Journal:  Heart Fail Rev       Date:  2013-11       Impact factor: 4.214

9.  Similar prevalence of enteroviral genome within the myocardium from patients with idiopathic dilated cardiomyopathy and controls by the polymerase chain reaction.

Authors:  P J Keeling; S Jeffery; A L Caforio; R Taylor; G F Bottazzo; M J Davies; W J McKenna
Journal:  Br Heart J       Date:  1992-12

10.  Detection of viral RNA in experimental coxsackievirus B3 myocarditis of mice using the polymerase chain reaction.

Authors:  I Okada; A Matsumori; B Kyu
Journal:  Int J Exp Pathol       Date:  1992-12       Impact factor: 1.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.